Dominari Holdings Inc
F:BP2A
Dominari Holdings Inc
F:BP2A
Price:
2.52
EUR
3.28%
Market Closed
Market Cap:
€15m
Relative Value
The Relative Value of one
BP2A
stock under the Base Case scenario is
12.17
EUR.
Compared to the current market price of 2.52 EUR,
Dominari Holdings Inc
is
Undervalued by 79%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BP2A
Relative Value
Base Case
12.17
EUR
Undervaluation 79%
Multiples Across Competitors
BP2A Competitors Multiples
Dominari Holdings Inc Competitors
Dominari Holdings Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Dominari Holdings Inc
F:BP2A
|
47.5m EUR | 0.5 | 0.4 | 2.3 | 2.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.9B USD | 6.7 | 97.4 | 16 | 22.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.9B USD | 5.4 | 25.7 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178.6B USD | 6.1 | 21 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.4B USD | 9.6 | 29.3 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.4B USD | 5.6 | 17.8 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.5B AUD | 3.2 | 35.8 | 11.8 | 14.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.8 | 34.7 | 37.6 | 38.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
